Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/FJC.0000000000000233 http://scihub22266oqcxt.onion/10.1097/FJC.0000000000000233 C4461388!4461388!25714598     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cardiovasc+Pharmacol 2015 ; 65 (6): 611-9 Nephropedia Template TP {{tp|p=25714598|t=2015. First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin |pdf=|usr=}}{{25714598}} gab.com Text First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin JO: J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25714598 #FOAvip Inclacumab, a novel monoclonal antibody against P-selectin in development for the treatment and prevention of atherosclerotic cardiovascular diseases, was administered in an ascending single-dose study as intravenous infusion to evaluate safety, pharmacokinetics, and pharmacodynamics. Fifty-six healthy subjects were enrolled in this randomized, double-blind placebo-controlled study. Each dose level (0.03?20 mg/kg) was investigated in separate groups of 8 subjects (6 on inclacumab, 2 on placebo). Platelet?leukocyte aggregates, free/total soluble P-selectin concentration ratio, drug concentrations, bleeding time, platelet aggregation, antibody formation, and routine laboratory parameters were measured frequently until 32 weeks. Pharmacokinetic profiles were indicative of target-mediated drug disposition. Platelet?leukocyte aggregate inhibition and soluble P-selectin occupancy showed dose dependency and were strongly correlated to inclacumab plasma concentrations, with IC50 of 740 and 4600 ng/mL, respectively. Inclacumab was well tolerated by the majority of subjects and did neither affect bleeding time nor platelet aggregation. These findings allowed the investigation of the potential beneficial therapeutic use of inclacumab in patient study. Twit Text FOAVip First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin ????J Cardiovasc Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25714598 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25714598 #FOAvip English Wikipedia <ref>{{Cite pmid|25714598}}</ref> First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin #MMPMID25714598 Schmitt C; Abt M; Ciorciaro C; Kling D; Jamois C; Schick E; Solier C; Benghozi R; Gaudreault J J Cardiovasc Pharmacol 2015[Jun]; 65 (6): 611-9 PMID25714598show ga Inclacumab, a novel monoclonal antibody against P-selectin in development for the treatment and prevention of atherosclerotic cardiovascular diseases, was administered in an ascending single-dose study as intravenous infusion to evaluate safety, pharmacokinetics, and pharmacodynamics. Fifty-six healthy subjects were enrolled in this randomized, double-blind placebo-controlled study. Each dose level (0.03?20 mg/kg) was investigated in separate groups of 8 subjects (6 on inclacumab, 2 on placebo). Platelet?leukocyte aggregates, free/total soluble P-selectin concentration ratio, drug concentrations, bleeding time, platelet aggregation, antibody formation, and routine laboratory parameters were measured frequently until 32 weeks. Pharmacokinetic profiles were indicative of target-mediated drug disposition. Platelet?leukocyte aggregate inhibition and soluble P-selectin occupancy showed dose dependency and were strongly correlated to inclacumab plasma concentrations, with IC50 of 740 and 4600 ng/mL, respectively. Inclacumab was well tolerated by the majority of subjects and did neither affect bleeding time nor platelet aggregation. These findings allowed the investigation of the potential beneficial therapeutic use of inclacumab in patient study. äFirst-in-man Study With Inclacumab, a Human Monoclonal Antibody Agains(epmc).pdf DeepDyve Pubget Overpricing